CAIHL read · Jun 11, 2026
FDA's Greenlight of Old Chemical Offers Chance To Restore Faith in Sunscreen
Framework
What CAIHL does
Critical AI Health Literacy (CAIHL) is an analytical lens — Hugo Campos and Liz Salmi's 2025 National Academy of Medicine commentary, "Critical AI Health Literacy as Liberation Technology." It applies Paulo Freire's theory of critical literacy to health AI.
The central question CAIHL asks is whose interests does this AI actually serve? Four dimensions answer it: who is the primary user, where is it hosted, whose interests does it advance, and does it expand or constrain patient agency.
This deep-read separates the four dimensions on a single item from the day's scan, so you can see the specific structural shape of the AI in question — not just the bucket it landed in.
The four dimensions
How this item reads through CAIHL
Primary user
patient
Patients, families, and care partners are the primary users of this AI.
Hosting
government
Hosted or controlled by a government agency or program.
Interests
patient-aligned
Interest structure prioritizes patients. Operates on a philanthropic, public-service, or advocacy footing.
Agency
expanding
Expands patient capabilities, supports their questions, increases their ability to act on their own values across and beyond health systems.
Editor's CAIHL read
One-sentence synthesis
Regulatory-trust restoration moment in OTC product approval; expanding agency for the patient who reads the label.
In the scan
How this item appeared in the daily scan
Editor's note: The bemotrizinol approval is the test case for whether the FDA can be seen to act in patients' interests after the institutional trust drift. The patient evaluating an OTC product is doing the same evaluation the patient evaluating an AI tool is doing.
Summary: KFF Health News: FDA approves bemotrizinol — an established sunscreen filter long used outside the US — as a chance for consumer trust in over-the-counter sun protection to be rebuilt after a long approvals lag.
methodology
Limitations
CAIHL is a lens, not a verdict. The four dimensions are conditions of use — reassess them when a tool's business model, deployment context, or patient behavior changes. See the NAM commentary for the full framework.